October 26, 2019 11:22am

There is a slew of earnings’ releases next week, is the sector prepared and in November – NO

The week in review, the numbers” speak for themselves … after two (2) positive and three (3) negative closes

It's a daunting task to define risk parameters, seeing the unforeseen; on the basis of my own “rules”, I set-up my own “warning analysis” which isn’t machine oriented!  


 

The sector is what it is, until it isn’t and even then it doesn’t seem to be… so be rady for anything!

 

The Dow closed UP +152.53 points (+0.57%), the S&P closed UP +12.26 points (+0.41%) and the NASDAQ closed UP +57.32 points (+0.70%)

 

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Friday the IBB closed down -0.15% while the XBI closed up +1.20%
  • Thursday the IBB closed up +0.10% while the XBI closed down -0.29%
  • Wednesday the IBB closed up +0.34% while the XBI closed down -0.31%
  • Tuesday the IBB closed up +1.72% while the XBI closed up +0.65%
  • Monday the IBB closed up +1.31% while the XBI closed up +1.44%

 

The advance/decline line scenario of 45 covered companies:  

  • Friday the close was positive with an A/D line of 30/11, 1 flat, 1 reversed merged (HSGX) and 2 acquired;
  • Thursday the close was negative with an A/D line of 13/27, 3 flats, 1 reversed merged (HSGX) and 2 acquired;
  • Wednesday the close was negative with an A/D line of 16/26, 0 flats, 1 reversed merged (HSGX) and 2 acquired;
  • Tuesday the close was negative with an A/D line of 16/23, 3 flats, 1 reversed merged (HSGX) and 2 acquired;
  • Monday the close was positive with an A/D line of 28/13, 1 flats, 1 reversed merged (HSGX) and 2 acquired;

 

Henry’omics:

My universe of 45 equities closed up on Friday as investors’ cheered apparent progress on the U.S.-China trade front?

The week in review, the numbers” speak for themselves … after two (2) positive <Monday and Friday> and three (3) negative closes

On the data front, consumer sentiment dipped slightly in October to 95.5, according to the University of Michigan's Surveys of Consumers. That's down from a preliminary reading of 96, but above a final September print of 93.2 <CNBC>.

 

My exhortation: end the month, end the month!

Get earnings’ season over – we just might see some appreciation to the oversold … If numbers reflect the guidance going forward!

 

Decliners:

  • ReNeuron (RENE.L -$8.00);
  • Solid Biosciences (SLDB -$0.51);
  • Homology Biosciences (FIXX -$0.20);
  • Cesca Therapeutics (KOOL -$0.18);
  • AxoGen (AXGN -$0.16);

Incliners:

  • Sage Therapeutics (SAGE +$4.56 after Thursday’s -$0.50, Wednesday’s +$2.58 and Tuesday’s -$1.22);
  • uniQure (QURE +$3.41 after Thursday’s +$3.52 and Wednesday’s -$0.85);
  • Regenxbio (RGNX +$2.11);
  • BioMarin Pharmaceuticals (+$1.74 after Thursday’s +$0.44, Wednesday’s +$1.28 and Tuesday’s -$0.99);
  • Global Blood Therapeutics (GBT +$1.48);

 

The percentage (%) indicators: 

  • Friday’s range of the 30 upside was +0.07% (IONS) to +8.65% (ADVM) while the 11 downside ranged from -1.34% (AXGN) to -5.46% (RENE.L);

 

  • Thursday’s range of the 13 upside was +0.08% (AXGN) to +8.28% (QURE) while the 27 downside ranged from -0.23% (SGMO) to -6.91% (KOOL);

 

  • Wednesday’s range of the 16 upside was +0.33% (AGTC) to +19.47% (VSTM) while the 26 downside ranged from -0.13% (RGNX) to -5.79% (KOOL);

 

  • Tuesday’s range of the 16 upside was +0.29% (CLLS) to +6.17% (SLDB) while the 23 downside ranged from -0.08% (MDXG) to -5.97% (AXGN);

 

  • Monday’s range of the 28  upside was +0.70% (SAGE) to +7.22% (PSTI +$0.22) while the 13 downside ranged from -0.14% (ONVO) to -7.80% (RENE.L);

 

 

Upside volume stats:  to compare

  • Friday: 9 out of the 30 upside had higher than the 3 month average volume;
  • Thursday: 3 out of the 13 upside had higher than the 3 month average volume;
  • Wednesday: 3 out of the 16 upside had higher than the 3 month average volume;
  • Tuesday: 2 out of the 16 upside had higher than the 3 month average volume;
  • Monday: 5 out of the 28 upside had higher than the 3 month average volume;

Downside volume stats:

  • Friday: 0 out of the 11 downside had higher than the 3 month average volume;
  • Thursday: 3 out of the 27 downside had higher than the 3 month average volume;
  • Wednesday: 2 out of the 26 downside had higher than the 3 month average volume;
  • Tuesday: 8 out of the 23 downside had higher than the 3 month average volume;
  • Monday: 3 out of the 13 downside had higher than the 3 month average volume;

 

1 flat – BSTG with 1 reverse merged (HSGX), 2 acquired (AST & OSIR) and Spark Therapeutics’ (ONCE) acquisition by Roche could be soon according to rumors from FTC by year’s end.

 

October’s sessions:

Friday closed POSITIVE with 11 decliners, 30 advancers, 1 flat, 1 reverse merged (HSGX) and 2 acquired (AST & OSIR);

Thursday closed NEGATIVE with 27 decliners, 13 advancers, 2 flats, 1 reverse merged (HSGX) and 2 acquired (AST & OSIR);

Wednesday closed NEGATIVE with 26 decliners, 16 advancers, 0 flats, 1 reverse merged (HSGX) and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 23 decliners, 16 advancers, 3 flats, 1 reverse merged (HSGX) and 2 acquired (AST & OSIR);

Monday closed POSITIVE with 13 decliners, 28 advancers, 1 flat, 1 reverse merged (HSGX) and 2 acquired (AST & OSIR);

Friday closed NEGATIVE with 33 decliners, 7 advancers, 2 flats, 1 reverse merged (HSGX) and 2 acquired (AST & OSIR);

Thursday closed POSITIVE with 17 decliners, 25 advancers, 0 flat, 1 reverse merged (HSGX) and 2 acquired (AST & OSIR);

Wednesday closed POSITIVE with 19 decliners, 23 advancers, 0 flat, 1 reverse merged (HSGX) and 2 acquired (AST & OSIR);

Tuesday closed POSITIVE with 9 decliners, 32 advancers, 1 flat, 1 reverse merged (HSGX) and 2 acquired (AST & OSIR);

Monday closed NEGATIVE with 29 decliners, 12 advancers, 1 flat, 1 reverse merged (HSGX) and 2 acquired (AST & OSIR);

Friday closed POSITIVE with 13 decliners, 29 advancers, 0 flat, 1 reverse merged (HSGX) and 2 acquired (AST & OSIR);

Thursday closed POSITIVE with 17 decliners, 23 advancers, 2 flats, 1 reverse merged (HSGX) and 2 acquired (AST & OSIR);

Wednesday closed NEGATIVE with 27 decliners, 12 advancers, 3 flats, 1 reverse merged (HSGX) and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 38 decliners, 4 advancers, 1 flat and 1 reverse merged (HSGX), 2 acquired (AST & OSIR);

Monday closed NEGATIVE with 25 decliners, 17 advancers, 1 flat and 2 acquired (AST & OSIR);

Friday closed POSITIVE with 17 decliners, 24 advancers, 2 flats and 2 acquired (AST & OSIR);

Thursday closed NEUTRAL with 21 decliners, 21 advancers, 1 flat and 2 acquired (AST & OSIR);

Wednesday closed NEGATIVE with 22 decliners, 18 advancers, 3 flats and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 36 decliners, 5 advancers, 2 flat and 2 acquired (AST & OSIR);

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.